BioNTech, the German biotech group behind the first approved Covid-19 vaccine, warned there was “no data” to support moves to delay the second dose of the jab with the aim of reaching as many people as possible with limited supplies.
研發了首款獲批新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗的德國生物科技企業BioNTech警告稱，爲了在疫苗供應有限的情況下儘可能覆蓋更多人而延遲第二針接種的舉動，是「沒有數據」支持的。
您已閱讀5%（336字），剩餘95%（6307字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。